Robert E. Hoffman named CEO of CytoDyn as Jacob P. Lalezari steps into Head of Research and Translational Sciences

CytoDyn (CYDY) named Robert Hoffman as CEO, effective October 20, 2026. He replaces Dr. Jacob Lalezari, who will lead research and translational sciences. Hoffman will also retain his role as principal accounting officer. According to the company, Lalezari will focus on advancing leronlimab in solid-tumor oncology.

CytoDyn Inc. reported a net loss of $42.7M for fiscal 2026, a significant decline from a $3.7M net income in 2025. The company's cash reserves stood at $11.9M, with working capital and accumulated deficits raising concerns about its ability to continue operations. CytoDyn cited clinical development progress and strategic partnerships as key highlights.

Moody's upgraded Oshkosh Corporation's (NYSE:OSK) rating to Baa2 from Baa3, citing a stronger business mix and stable outlook. The company's focus on Vocational and Transport segments is expected to drive revenue growth of 3% in 2026 and 9% in 2027, with EBITA margins expanding to around 9% by 2027. Moody's projects solid free cash flow and financial leverage below 1.5x through 2027.

BHP Group reported a 19% drop in copper production in Q1 FY2027 due to maintenance and disruptions, but stronger commodity prices, including a 53% rise in copper prices, supported earnings. Iron ore production rose 4%, and coal output increased. BHP maintained its annual production and cost guidance.

Morgan Stanley upgraded Global-E Online (GLBE) to Overweight on Oct. 19, citing undervalued sales trends. The bank anticipates robust sales growth and believes the market underestimates the company's recent same-store sales gains and their potential duration.

Veradermics' (MANE) oral hair-loss drug VDPHL01 met all goals in a Phase 3 trial, showing significant hair growth. Shares rose over 11% intraday. The drug is an extended-release oral minoxidil formulation, aiming to improve convenience and adherence. Veradermics plans to seek regulatory approval, but direct comparisons with generic minoxidil are pending.